Express News | Mkt Capital: Request Seres Board Immediately Provide Stockholders With Facts for Its Engagement With Nestlé Ahead of Sept 30 Closing of Vowst Sale
Express News | Mkt Capital, Other Seres Therapeutics Stockholders: Express Concern on Report That Co Rebuffed Outright Takeover Offer From Nestlé
Express News | Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé
Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé
12 Health Care Stocks Moving In Thursday's After-Market Session
Seres Therapeutics Stockholders Approve Sale of VOWST to Nestlé Health Science; Sale Expected to Close on September 30
Express News | Seres Therapeutics Stockholders Approve Sale of Vowst™ to Nestlé Health Science; Sale Expected to Close on September 30
Canaccord Genuity Maintains Buy on Seres Therapeutics, Maintains $10 Price Target
Seres Therapeutics Analyst Ratings
Oppenheimer Sticks to Their Hold Rating for Seres Therapeutics (MCRB)
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $10
CCORF analyst John Newman maintains $Seres Therapeutics(MCRB.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 38.6% and a
Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (MCRB), BioMarin Pharmaceutical (BMRN) and Exact Sciences (EXAS)
Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
Express News | Seres Therapeutics Inc - Ser-155 Shows Well Tolerated Safety Profile, No Serious Adverse Events
Express News | Seres Therapeutics Reports Ser-155 Phase 1B Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct)
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Seres Therapeutics Jumps on Speculation of Nestle Acquisition Offer
Watching Seres Therapeutics; Traders Circulate Unconfirmed M&A Blog Comments Suggesting Nestle Has Offered To Acquire The Company For $750M, Or $6-$6.50/Share
Seres Therapeutics Shares Halted To The Upside; Up 20.00%
2024 Microbiome Market Trends Report Featuring Seres Therapeutics, Rebiotix, IFF (DuPont), Chr. Hansen (Novonesis), Nestle, Probi, Lactobio, Pivot Bio, and LanzaTech - ResearchAndMarkets.com